Skip to content

Changes in serum and urinary concentrations of glycocalyx metabolites in patients with ARDS

Changes in serum and urinary concentrations of glycocalyx metabolites in patients with ARDS

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300078075
Enrollment
Unknown
Registered
2023-11-28
Start date
2021-10-21
Completion date
Unknown
Last updated
2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute respiratory distress syndrome

Interventions

ARDS patients who can aspirate pulmonary edema fluid/ARDS patients who cannot aspirate pulmonary edema fluid/Patients with cardiogenic pulmonary edema who can aspirate pulmonary edema fluid:None
Healthy control group:None

Sponsors

Yantai Affiliated Hospital of Binzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) The patient is =18 years old; (2) Voluntary informed consent signed by the patient or guardian; (3) Fulfilment of the diagnostic criteria for ARDS as defined by Berlin (1. Acute or progressive dyspnoea presenting within 1 week of a clear trigger.2. Chest radiograph/chest CT showing infiltrative shadows in both lungs, which could not be fully explained by pleural effusion, lobar/total lung atelectasis, and nodular shadows.3. Respiratory failure that could not be fully explained by cardiac failure and fluid overload.4. Hypoxaemia PaO2 = (300 mmHg); (4) Patients with undiluted pulmonary oedema fluid that could be aspirated via suction tube or fibreoptic bronchoscope during hospitalisation, and patients with ARDS who were unable to aspirate pulmonary oedema fluid during the same period of time on a 1:1 match; (5) Patients with cardiogenic pulmonary oedema who can aspirate pulmonary oedema fluid.

Exclusion criteria

Exclusion criteria: (1) Combination of severe irreversible advanced diseases, such as various cancers and advanced cirrhosis; (2) Pregnant or lactating patients; (3) Other conditions that, in the opinion of the investigator, make it inappropriate for patients to participate in this study.

Design outcomes

Primary

MeasureTime frame
Glycocalyx metabolites;28 day mortality rate;

Secondary

MeasureTime frame
Demographic characteristics;blood biochemistry;Duration of mechanical ventilation;Length of hospitalisation;Length of ICU stay;90 day survival rate;

Countries

CHINA

Contacts

Public ContactZhijiang Qi

Yantai Affiliated Hospital of Binzhou Medical University

thymcglqi@163.com+86 188 0128 3218

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026